Lucid Diagnostics (NASDAQ:LUCD) Receives "Sell (E+)" Rating from Weiss Ratings

Key Points

• Lucid Diagnostics (NASDAQ:LUCD) has been assigned a "Sell (E+)" rating by Weiss Ratings, with other analysts offering a mix of ratings including several "Buy" recommendations.
• The company's stock currently trades at $1.18, down 0.4%, with a consensus target price of $3.70 amid a significant percentage (74.01%) of shares owned by institutional investors.
• Insider Director Dennis Matheis increased his stake by purchasing 100,000 shares at $1.02 each, boosting his ownership by 17.69% to a total of approximately 665,443 shares.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report)'s stock had its "sell (e+)" rating reissued by analysts at Weiss Ratings in a report released on Tuesday,Weiss Ratings reports.

A number of other brokerages also recently issued reports on LUCD. Ascendiant Capital Markets upped their price objective on shares of Lucid Diagnostics from $7.75 to $8.00 and gave the stock a "buy" rating in a research report on Monday, October 6th. Needham & Company LLC reissued a "buy" rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Wednesday, August 13th. Wall Street Zen raised shares of Lucid Diagnostics from a "sell" rating to a "hold" rating in a research report on Tuesday. Finally, BTIG Research increased their target price on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the company a "buy" rating in a research report on Friday, September 5th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $3.70.

Lucid Diagnostics Trading Down 0.4%

Shares of LUCD traded down $0.01 on Tuesday, reaching $1.18. The company's stock had a trading volume of 409,131 shares, compared to its average volume of 1,086,935. Lucid Diagnostics has a twelve month low of $0.75 and a twelve month high of $1.80. The stock has a market capitalization of $156.84 million, a PE ratio of -0.99 and a beta of 1.19. The firm has a fifty day moving average of $1.10 and a 200-day moving average of $1.20.

Insider Transactions at Lucid Diagnostics

In other news, Director Dennis Matheis bought 100,000 shares of the firm's stock in a transaction on Wednesday, August 20th. The stock was acquired at an average cost of $1.02 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director owned 665,443 shares of the company's stock, valued at approximately $678,751.86. This represents a 17.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.80% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. purchased a new position in shares of Lucid Diagnostics during the first quarter valued at approximately $2,813,000. Geode Capital Management LLC grew its position in Lucid Diagnostics by 420.3% during the second quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company's stock valued at $1,814,000 after buying an additional 1,274,194 shares during the period. Luminus Management LLC grew its position in Lucid Diagnostics by 14.8% during the third quarter. Luminus Management LLC now owns 912,805 shares of the company's stock valued at $922,000 after buying an additional 117,975 shares during the period. Ghisallo Capital Management LLC bought a new stake in Lucid Diagnostics during the first quarter valued at approximately $629,000. Finally, XML Financial LLC bought a new stake in Lucid Diagnostics during the first quarter valued at approximately $266,000. 74.01% of the stock is owned by hedge funds and other institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.